ArticleJournal of cachexia, sarcopenia and muscle2014
Formoterol in the treatment of experimental cancer cachexia: effects on heart function.
Article in Journal of cachexia, sarcopenia and muscle, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Anabolic deficits and divergent unfolded protein response underlie skeletal and cardiac muscle growth impairments in the Yoshida hepatoma tumor model of cancer cachexia.Physiological reports · 2024Article
- Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.Nature reviews. Clinical oncology · 2023Review
- Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy.Frontiers in oncology · 2023Article
- Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors.Cells · 2022Review
- Review
- Cardiac Complications: The Understudied Aspect of Cancer Cachexia.Cardiovascular toxicology · 2022Review
- Evidence for reciprocal network interactions between injured hearts and cancer.Frontiers in cardiovascular medicine · 2022Review
- Repurposing of Antibiotic Sulfisoxazole Inhibits Lipolysis in Pre-Clinical Model of Cancer-Associated Cachexia.Biology · 2021Article
- Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model.OncoTargets and therapy · 2021Article
- Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).European journal of heart failure · 2020Article
- The animal cachexia score (ACASCO).Animal models and experimental medicine · 2019Article
- Therapeutic strategies against cancer cachexia.European journal of translational myology · 2019Article
- Skeletal muscle wasting in chronic heart failure.ESC heart failure · 2018Review
- Muscle wasting and sarcopenia in heart failure and beyond: update 2017.ESC heart failure · 2017Review
- Cardiac muscle wasting in individuals with cancer cachexia.ESC heart failure · 2017Article
- Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.Journal of cachexia, sarcopenia and muscle · 2017Article
- Cancer-induced muscle wasting: latest findings in prevention and treatment.Therapeutic advances in medical oncology · 2017Review
- Article
- Publication trends in cachexia and sarcopenia in elderly heart failure patients.Wiener klinische Wochenschrift · 2016Review
- Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.Journal of cachexia, sarcopenia and muscle · 2016Article
Corrections and comments
- Erratum issuedCorrigendum.2015
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsFormoterol is a highly potent β2-adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species, resulting in skeletal muscle hypertrophy. Previous studies carried out in our laboratory have shown that formoterol treatment in tumour-bearing animals resulted in an amelioration of muscle loss through different mechanisms that include muscle apoptosis and proteolysis.
methodsThe study presented involved rats bearing the Yoshida AH-130 ascites tumour model-which induces a high degree of cachexia-treated with the beta-2 agonist formoterol (0.3 mg/kg BW).
resultsThe administration of formoterol to cachectic tumour-bearing rats resulted in a significant reduction of muscle weight loss. The treatment also increased lean body mass and body water. The treatment, however, did not influence heart weight, which was much decreased as a result of tumour burden. Untreated tumour-bearing rats showed important changes in parameters related with heart function:, left ventricle (LV) ejection fraction, fractional shortening, LV diameter and volume (diastolic) and LV stroke volume, LV mass and posterior wall thickness (PWT) (both systolic and diastolic). The administration of formoterol affected LV diameter and volume, LV stroke volume and LV mass.
conclusionsThe results suggest that formoterol treatment, in addition to reducing muscle wasting, does not negatively alter heart function-in fact, some cardiac parameters are improved-in animals affected by cancer cachexia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.